Search

everythinglearnresearchcommunity

for

Search:↓

The DHT itch is linked to hair loss and persists despite finasteride use; switching to dutasteride helped alleviate the itch and promoted regrowth. Some users suggest seborrheic dermatitis as a cause and recommend treatments like medicated shampoos, vitamin D, and minoxidil.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

Anti-inflammatories like curcumin, quercetin, and vitamin E may help with hair loss when used alongside treatments like finasteride and dutasteride. Ketoconazole is also noted for reducing scalp inflammation and improving scalp health.

The user is unhappy with the results of their second hair transplant, feeling that grafts were wasted on an already transplanted hairline instead of increasing mid-scalp density. They regret stopping medications like Dutasteride, Minoxidil, and RU58841, which led to significant hair loss, and plan to restart them.

The user is experiencing rapid hair loss despite using dutasteride, finasteride, and minoxidil, and is concerned about high estradiol and testosterone levels. They are advised to consult an endocrinologist for potential hormonal imbalances.

A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.

The potential release date for results from a phase 2 trial of Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841. It was agreed that the results are expected to be released in June 2022.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

User discusses hair loss treatments, including fluridil, minoxidil, tretinoin, melatonin, stemoxydine, ketoconazole, and piroctone olamine. They suggest that shedding healthy terminal hairs may be bad, while shedding weaker hairs could indicate a beneficial treatment effect.

Reducing sebum can indirectly lower DHT levels, with treatments like accutane, tretinoin, and green tea extract acting as DHT blockers. Accutane can lower DHT levels by reducing 5α-reductase activity, but its impact on hair varies.

The conversation discusses using soy isoflavones and capsaicin for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started taking finasteride, which initially slowed hair shedding and slightly thickened hair. The doctor recommended iron and vitamin D supplements, and the user is considering minoxidil but wants to stabilize shedding first.

A user with aggressive male pattern baldness found that topical melatonin significantly reduced their hair shedding to 1 or 2 hairs per day and noticed some thickening of side hair. They tried many treatments like finasteride and minoxidil with little success, but topical melatonin showed immediate results in reducing hair loss.

Hair loss due to DHT is causing distress, with Minoxidil, finasteride, and RU58841 being potential treatments. The conversation includes humor and frustration about the topic.

A 20-year-old saw significant hair regrowth after 9 months of using DHT blockers (finasteride and dutasteride) and 6 months of hormone replacement therapy (HRT) with estradiol. The regrowth is attributed to low testosterone and high estradiol levels, without using Minoxidil.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

A new hair loss treatment called TDM-105795 is discussed as a potential replacement or add-on to Minoxidil. Users express hope for new effective treatments.

Hair loss treatments, specifically 5AR inhibitors, can impact neurosteroids and sexual health. The effects of topical fin/dut on tissue-specific DHT levels are unclear.

The user started using 1mg finasteride and Regaine foam post-hair transplant, noticing significant hair growth at three months. They experienced testicular cramps as a side effect but no other issues, and are considering microneedling for further improvement.

The conversation discusses why DHT (dihydrotestosterone) negatively affects scalp hair but promotes growth elsewhere on the body. Various opinions include genetic predispositions, differences in hair follicle reactions to DHT, and the potential role of Omega-3 in reducing inflammation and promoting hair health.

Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hair loss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.

RU58841 stopped scalp itching for the user, providing relief from persistent itchiness associated with hair loss. Some users reported side effects like chest pain, while others found relief with different treatments like mometasone.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

The user is happy with their hair regrowth after two years of using finasteride, minoxidil, and biotin, reporting no side effects. They noticed significant improvement after one year and maintained consistent treatment to avoid shedding.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.